Yes. A person can have autoimmune type 1 diabetes and insulin resistance at the same time. Type 1 diabetes describes an immune-related loss of insulin-producing cells. Insulin resistance describes a reduced response to insulin in tissues such as muscle and liver. These are different processes, and one does not prevent the other.
This matters when someone with established type 1 diabetes develops weight changes, higher blood pressure, abnormal cholesterol, or changing insulin requirements. Laboratory assessment can support a broader health review, but no single routine result measures the whole problem. Ulta Lab Tests offers relevant options, including hemoglobin A1C, a lipid panel, selected apolipoprotein B (ApoB), urine albumin-to-creatinine ratio (uACR), and creatinine with reported eGFR, for discussion with a healthcare professional.
The Diabetes and Prediabetes Blood Tests guide explains the overall testing framework. This article focuses on metabolic risk in established type 1 diabetes; the adult-onset autoimmune diabetes cornerstone addresses how diabetes type is evaluated.
“Double diabetes” is an informal expression sometimes used when type 1 diabetes coexists with insulin resistance or features commonly associated with type 2 diabetes. It is not a diagnosis established by one laboratory cutoff. Using the term should not obscure the person's confirmed autoimmune disease or continuing need for insulin.
The updated 2026 ADA/EASD adult type 1 diabetes consensus recognizes that obesity and insulin resistance can coexist with type 1 diabetes. A person with a larger body can have autoimmune diabetes, and a lean person can have reduced insulin sensitivity. Clinical history and appropriate classification evidence matter more than appearance. [1]
There is also a difference between changing insulin sensitivity and changing diabetes type. Improving sensitivity may change treatment needs under professional supervision. It does not mean that an autoimmune condition has disappeared.
Long-term diabetes care includes cardiovascular and kidney health as well as glucose management. Blood pressure, smoking, family history, physical activity, sleep, medications, and existing complications all influence the clinical picture. Obesity is one possible contributor to metabolic risk, but its effects and treatment priorities vary between individuals. [2]
A person can meet an A1C goal while still having high cholesterol or albumin in the urine. Conversely, a favorable cholesterol result does not show that daily glucose levels are stable. Separating these questions helps avoid treating one reassuring number as proof that every part of health is addressed.
Use the Metabolic Health and Weight-Loss Blood Tests guide for the broader metabolic framework and the Heart Health Blood Tests guide for cardiovascular risk interpretation.
| Situation | Possible laboratory focus | Additional assessment |
|---|---|---|
| Weight gain or a change in waist size | A1C and lipid panel if due | Nutrition, activity, sleep, medicines, and weight trajectory |
| Increasing insulin requirements | Results selected for the suspected cause | Illness, delivery problems, injection sites, technique, timing, meals, and activity |
| High triglycerides or an unclear cholesterol-risk pattern | Lipid panel and selected ApoB | Overall cardiovascular risk and secondary contributors |
| High blood pressure or established kidney concerns | uACR and creatinine with reported eGFR | Valid blood-pressure measurements and prior trends |
| Frequent low readings despite an apparently favorable average | A1C interpreted with meter or sensor data | Hypoglycemia prevention and treatment-plan review |
| Sudden deterioration with vomiting or unusual breathing | Immediate clinical assessment | Possible acute insulin deficiency; routine metabolic testing is inappropriate |
Discuss a substantial or unexplained change even if routine annual testing is not due. If high readings follow a pump problem, missed insulin, or acute illness, follow the diabetes team's sick-day and device-failure instructions promptly. Persistent vomiting, deep or rapid breathing, confusion, or inability to keep fluids down requires emergency care.
| Test | Purpose and usefulness | High, low, or discordant results |
|---|---|---|
| Hemoglobin A1C | Estimates recent average glucose exposure; useful for ongoing diabetes assessment | A higher result may reflect greater exposure. A low result can conceal frequent lows or reflect altered red-cell biology. It does not quantify insulin resistance. |
| Lipid panel | Reports cholesterol and triglyceride measures used in cardiovascular-risk assessment | Higher LDL or non-HDL cholesterol and elevated triglycerides may change the care plan. A high HDL result does not cancel other risks. |
| Apolipoprotein B (ApoB) | Estimates the concentration of atherogenic lipoprotein particles; a selective risk-refinement option | A higher value can reveal particle burden not fully reflected by LDL cholesterol. A lower value does not rule out cardiovascular disease. |
| Urine albumin-to-creatinine ratio (uACR) | Assesses urinary albumin relative to urine concentration; contributes to kidney-risk assessment | Persistent elevation can indicate kidney damage. Exercise, infection, and other temporary factors can affect a sample. |
| Creatinine with reported eGFR | Assesses a blood filtration marker and calculated estimate of kidney function | Higher creatinine or lower eGFR warrants contextual review. Normal filtration does not exclude albuminuria. |
For uACR, the linked Ulta product is Albumin, Random Urine with Creatinine. This is a urine test; the creatinine blood test answers the separate filtration question. Avoid substituting a serum albumin measurement for a urine albumin assessment.
A conventional cholesterol panel describes the amount of cholesterol carried in different lipoprotein groups. ApoB adds information about atherogenic particle concentration. The measures can be discordant, including in people with elevated triglycerides or metabolic risk. A clinician may use it when additional information could change management. [3]
It is not necessary to order every advanced lipid measurement together. An additional result is useful when there is a clear question and an agreed way to act on the answer. Neither a conventional panel nor ApoB shows the location of arterial plaque.
Diabetes kidney disease may develop without obvious symptoms. Urinary albumin and estimated filtration provide complementary information, and kidney findings can influence overall risk assessment and medication decisions. A normal result in one does not make the other unnecessary when both are due. [4]
The testing schedule depends on diabetes duration, prior abnormalities, and the clinical plan. A new abnormality may need confirmation or more immediate assessment. The Kidney Function Tests guide explains the distinction between a temporary result, persistent kidney disease, and a changing trend.
Research methods and routine clinical decisions are different. Calculations such as HOMA-IR assume a particular relationship between the body's own fasting insulin production and glucose. Injected insulin, limited endogenous secretion, and assay differences complicate that relationship in type 1 diabetes.
Similarly, C-peptide measures endogenous insulin secretion; it is not a direct insulin-sensitivity test. A low result may reflect loss of insulin-producing cells while substantial insulin resistance is also present. Neither a routine insulin measurement nor C-peptide should be sold as a single answer to the metabolic-risk question in established type 1 diabetes. [1,5]
Insulin dose alone is also imperfect evidence. Delivery technique, infusion-site problems, illness, steroid exposure, meal patterns, and changes in activity can influence requirements. Reviewing those factors can be more useful than ordering another number.
These are purposes, not escalating packages everyone should buy. Start by identifying what has already been measured, what is due, and what decision a new result would support.
Consider a fictional example: someone has an A1C at their personal goal, elevated triglycerides, and a blood-pressure trend above the range agreed with their clinician. The average glucose result is useful, but a cardiovascular review still matters. A selected ApoB could clarify a specific lipid question; it would not establish insulin resistance on its own.
In a different example, weight and insulin requirements have risen while laboratory findings remain similar. That still warrants a conversation about delivery, meals, activity, sleep, medication effects, and the person's priorities. The purpose of testing is to support that conversation, not to require an abnormal result before concerns are taken seriously.
Compare trends with medication changes, illness, and collection conditions recorded. Treatment goals are individualized, and a laboratory reference interval is not automatically the right cardiovascular or glucose target for every person.
A1C alone does not require fasting. Follow the exact lipid-order instructions; a clinician may request fasting for a particular triglyceride question. Do not improvise an insulin change to complete a fast. Arrange preparation with the diabetes team if there is a risk of low glucose.
For urine collection, report a urinary infection, fever, menstruation, recent strenuous exercise, or marked hyperglycemia. These can affect interpretation. A single elevated uACR usually needs evaluation of persistence rather than an immediate assumption of chronic kidney disease.
Weight care should account for hypoglycemia, food access, physical limitations, and the burden of diabetes management. Do not omit insulin for weight loss. Decisions about nutrition, exercise, weight medicines, or other treatment require a plan that maintains insulin safety. [2]
Eligible patients can review the linked tests, displayed prices, preparation instructions, and collection requirements online. Coordinate selection with the clinician managing diabetes, particularly if recent testing already covers some measurements. Read Direct-Access Lab Testing for ordering and follow-up considerations.
Laboratory access is most helpful when each result has a purpose and a responsible reviewer. No purchased panel replaces blood-pressure measurement, examination, glucose-device review, or an individualized treatment discussion.
Yes. Body size does not establish diabetes type. Autoimmune destruction of insulin-producing cells can occur in people across the weight spectrum, and insulin resistance may coexist. Classification depends on the clinical history and appropriate evidence. A weight change does not by itself mean a previous type 1 diabetes diagnosis was incorrect.
The phrase is usually informal shorthand for type 1 diabetes with insulin resistance or related metabolic features. It does not have one universally accepted laboratory definition. The practical priority is to address insulin needs, glucose patterns, cardiovascular risk, kidney health, and weight concerns without losing sight of the underlying autoimmune insulin deficiency.
No. Requirements can rise because of illness, medication effects, changes in meals or activity, or problems with insulin delivery. A clinician also reviews injection sites, pump function, timing, and the glucose pattern. A persistent increase may support a broader metabolic assessment, but the dose alone cannot establish the explanation.
It is not a simple diagnostic answer in someone using injected insulin. Assays vary in their response to insulin preparations, and endogenous production may be limited. Calculations developed around fasting endogenous secretion can therefore be misleading. Clinical assessment and established glucose, lipid, blood-pressure, and kidney measures generally provide more actionable information.
No. C-peptide helps assess the insulin the pancreas still produces. Its interpretation requires glucose and clinical context, including kidney function and collection timing. It can help selected classification questions, but does not directly measure tissue sensitivity to insulin. A person can have very low endogenous production and reduced insulin sensitivity together.
Not automatically. ApoB may add information when atherogenic particle concentration could differ from what LDL cholesterol suggests, or when a clinician needs further risk clarification. The decision depends on the existing results and whether the answer would change care. Ordering several overlapping advanced lipid tests is not inherently more useful.
It addresses one part of the picture. A1C does not measure blood pressure, cholesterol-related risk, kidney damage, or body composition, and it may hide daily highs and lows. Continue the broader health review appropriate for your diabetes history. Discuss the result together with glucose records, symptoms, and other relevant measurements.
Improved insulin sensitivity may change dose requirements, but it does not restore adequate insulin production in established type 1 diabetes. Never stop or restrict insulin to pursue weight loss. Work with the diabetes team on an approach that protects against hypoglycemia and ketoacidosis while addressing nutrition, activity, and individual treatment goals.
Type 1 diabetes and insulin resistance can coexist. Review due A1C, lipid panel, uACR, and creatinine testing, and discuss ApoB only when it answers an additional risk question. Use the linked Ulta options to support a coordinated plan that includes glucose safety, cardiovascular prevention, kidney care, and your own priorities.
Insulin resistance is reduced tissue responsiveness to insulin and can coexist with autoimmune type 1 diabetes. Evaluation combines clinical history, glucose patterns, cardiovascular risk, and kidney assessment rather than relying on one resistance test.
Relevant tests: A1C, lipid panel, selected ApoB, uACR, and creatinine with reported eGFR.
Ulta Lab Tests provides access to relevant laboratory options that eligible patients can incorporate into clinician-directed monitoring.
Educational information only; laboratory results require clinical interpretation and do not replace individualized medical care.
| Category | Linked tests and role |
|---|---|
| Glucose monitoring | Hemoglobin A1C — longer-term glucose monitoring. |
| Standard lipid assessment | Lipid Panel — cholesterol and triglyceride assessment. |
| Additional cardiovascular assessment | Apolipoprotein B — a conditional addition when particle-related risk assessment would affect care. |
| Kidney screening | Urine Albumin-to-Creatinine Ratio and Creatinine, interpreted with reported eGFR. |
| Tests discussed for their limitations | C-Peptide and Insulin — explain why endogenous insulin secretion and circulating insulin measurements do not provide a simple standalone diagnosis of insulin resistance in someone using injected insulin. |
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
